Health Condition 1: H332- Serous retinal detachment
Conditions
Interventions
Intervention1: Eplerenone: Mineralocorticoid antagonist, Eplerenone, has been successfully used in management of chronic CSCR. The drug has a high therapeutic index at dosage required to treat CSCR. T
Sponsors
AFMRC Office of DGAFMS
Eligibility
Inclusion criteria
Inclusion criteria: 1. Acute CSCR (defined as duration of less than 6 months) 2. Age group between 20-50 years
Exclusion criteria
Exclusion criteria: 1. Renal diseases 2. History of dyselectrolytemia 3. Hypertension 4. Patient expressing inability to follow up for minimum 32 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in central macular thickness on OCTTimepoint: 0,4,8,12,16,20,24,28 and 32 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| change in visual acuity from baseline, percentage of patients achieving complete disappearance of subretinal fluid on OCT. Changes occurring in choroidal vasculature and permeability on ICGA . changes in autofluorescence of macula and choroidal thickness on enhanced depth imaging OCT. Any adverse effects of Eplerenone.Timepoint: 0,4,8,12,16,20,24,28 & 32 weeks | — |
Countries
India
Contacts
Public ContactPradeep Kumar
Command Hospital Chandimandir
Outcome results
None listed